Genelux Corporation (GNLX)Healthcare | Biotechnology | Westlake Village, United States | NasdaqCM
2.52 USD
-0.03
(-0.982%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 3:10 a.m. EDT
The investment case for Genelux is currently broken by a combination of deteriorating financials and a hostile market structure. Fundamentally, the company is burning cash aggressively with negative operating margins and a massive payout ratio relative to its free cash flow, which is unsustainable without further capital raising. The balance sheet is fragile, and insider selling signals a lack of confidence from those closest to the business. While analysts project a recovery to the high teens, the current reality is a value trap where the market has priced in a failure to execute. The options market confirms this pessimism, with heavy put positioning acting as a floor against further decline while call buyers remain distant and speculative. With no dividend to provide income and a high risk of dilution from upcoming offerings, this is a security to avoid until there is concrete proof of a turnaround in both revenue growth and cash burn. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.134174 |
| AutoETS | 0.139830 |
| AutoARIMA | 0.139831 |
| AutoTheta | 0.140254 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 2.72 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.691 |
| Excess Kurtosis | -0.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 15.019 |
| Market Cap | 114,018,248 |
| Forward P/E | -3.35 |
| Beta | 0.58 |
| Website | https://www.genelux.com |
As of Oct. 10, 2026, 3:10 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest is concentrated deep in-the-money at strikes significantly above the current price, suggesting a hedge against a severe drop or a bet on a collapse. Call activity is sparse and heavily skewed toward out-of-the-money strikes far above current levels, indicating speculative hopes for a massive rally that lack immediate liquidity or volume confirmation. Implied volatility is elevated on the put side relative to the call side, reflecting fear of a gap-down event.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5321691 |
| Address1 | 2,625 Townsgate Road |
| Address2 | Suite 230 |
| All Time High | 40.98 |
| All Time Low | 1.6 |
| Ask | 3.2 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 231,300 |
| Average Daily Volume3 Month | 274,395 |
| Average Volume | 274,395 |
| Average Volume10Days | 231,300 |
| Beta | 0.578 |
| Bid | 1.8 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 0.361 |
| City | Westlake Village |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.52 |
| Current Ratio | 2.394 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.54 |
| Day Low | 2.485 |
| Debt To Equity | 15.019 |
| Display Name | Genelux |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,746,562,200 |
| Earnings Timestamp Start | 1,746,562,200 |
| Ebitda | -36,280,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.665 |
| Enterprise To Revenue | 12,084.531 |
| Enterprise Value | 96,676,248 |
| Eps Current Year | -0.815 |
| Eps Forward | -0.75167 |
| Eps Trailing Twelve Months | -0.85 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.5963 |
| Fifty Day Average Change | -0.076299906 |
| Fifty Day Average Change Percent | -0.02938794 |
| Fifty Two Week Change Percent | -53.21691 |
| Fifty Two Week High | 8.535 |
| Fifty Two Week High Change | -6.015 |
| Fifty Two Week High Change Percent | -0.7047452 |
| Fifty Two Week Low | 2.29 |
| Fifty Two Week Low Change | 0.23000002 |
| Fifty Two Week Low Change Percent | 0.100436695 |
| Fifty Two Week Range | 2.29 - 8.535 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,674,743,400,000 |
| Float Shares | 36,435,294 |
| Forward Eps | -0.75167 |
| Forward P E | -3.352535 |
| Free Cashflow | -15,252,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 25 |
| Fullday Change | -0.025000095 |
| Fullday Change Percent | -0.9842557 |
| Fullday Price | 2.52 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.0 |
| Gross Profits | 8,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12871 |
| Held Percent Institutions | 0.31009 |
| Implied Shares Outstanding | 45,245,335 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-01-26 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California. |
| Long Name | Genelux Corporation |
| Market | us_market |
| Market Cap | 114,018,248 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_11172383 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -35,596,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 113,565,790 |
| Number Of Analyst Opinions | 6 |
| Open | 2.53 |
| Operating Cashflow | -25,277,000 |
| Operating Margins | -4,552.75 |
| Overall Risk | 9 |
| Phone | 805 267 9889 |
| Previous Close | 2.545 |
| Price Eps Current Year | -3.0920246 |
| Price Hint | 4 |
| Price To Book | 6.9806094 |
| Price To Sales Trailing12 Months | 14,252.281 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.334 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0250001 |
| Regular Market Change Percent | -0.982322 |
| Regular Market Day High | 2.54 |
| Regular Market Day Low | 2.485 |
| Regular Market Day Range | 2.485 - 2.54 |
| Regular Market Open | 2.53 |
| Regular Market Previous Close | 2.545 |
| Regular Market Price | 2.52 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 151,793 |
| Return On Assets | -0.77889 |
| Return On Equity | -1.77931 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 45,245,335 |
| Shares Percent Shares Out | 0.0964 |
| Shares Short | 4,362,110 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,775,663 |
| Short Name | Genelux Corporation |
| Short Percent Of Float | 0.099300005 |
| Short Ratio | 17.24 |
| Source Interval | 15 |
| State | CA |
| Symbol | GNLX |
| Target High Price | 31.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 18.83333 |
| Target Median Price | 17.0 |
| Total Cash | 18,670,000 |
| Total Cash Per Share | 0.417 |
| Total Debt | 2,420,000 |
| Total Revenue | 8,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.7901 |
| Two Hundred Day Average Change | -0.27010012 |
| Two Hundred Day Average Change Percent | -0.09680661 |
| Type Disp | Equity |
| Volume | 151,793 |
| Website | https://www.genelux.com |
| Zip | 91,361 |